A NOVEL MECHANISM OF RETROVIRUS INACTIVATION IN HUMAN SERUM MEDIATED BY ANTI-ALPHA-GALACTOSYL NATURAL ANTIBODY

被引:162
作者
ROTHER, RP
FODOR, WL
SPRINGHORN, JP
BIRKS, CW
SETTER, E
SANDRIN, MS
SQUINTO, SP
ROLLINS, SA
机构
[1] ALEXION PHARMACEUT,DEPT IMMUNOBIOL,NEW HAVEN,CT 06511
[2] AUSTIN HOSP,ASUTIN RES INST,IMMUNOGENET MOLEC LAB,HEIDELBERG,VIC 3084,AUSTRALIA
关键词
D O I
10.1084/jem.182.5.1345
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Type C retroviruses endogenous to various nonprimate species can infect human cells in vitro, yet the transmission of these viruses to humans is restricted. This has been attributed to direct binding of the complement component C1q to the viral envelope protein p15E, which leads to classical pathway-mediated virolysis in human serum. Here we report a novel mechanism of complement-mediated type C retrovirus inactivation that is initiated by the binding of ''natural antibody'' [Ab] (anti-alpha-galactosyl Ab) to the carbohydrate epitope Gal alpha 1-3Gal beta 1-4GlcNAc-R expressed on the retroviral envelope. Complement-mediated inactivation of amphotropic retroviral particles was found to be restricted to human and other Old World primate sera, which parallels the presence of anti-alpha-galactosyl natural Ab. Blockade or depletion of anti-alpha-galactosyl Ab in human serum prevented inactivation of both amphotropic and ecotropic murine retroviruses. Similarly, retrovirus was not killed by New World primate serum except in the presence of exogenous anti-alpha-galactosyl Ab. Enzyme-linked immunosorbent assays revealed that the alpha-galactosyl epitope was expressed on the surface of amphotropic and ecotropic retroviruses, and Western blot analysis further localized this epitope to the retroviral envelope glycoprotein gp70. Finally, down-regulation of this epitope on the surface of murine retroviral particle producer cells rendered them, as well as the particles liberated from these cells, resistant to inactivation by human serum complement. Our data suggest that anti-alpha-galactosyl Ab may provide a barrier for the horizontal transmission of retrovirus from species that express the alpha-galactosyl epitope to humans and to other Old World primates. Further, these data provide a mechanism for the generation of complement-resistant retroviral vectors for in vivo gene therapy applications where exposure to human complement is unavoidable.
引用
收藏
页码:1345 / 1355
页数:11
相关论文
共 53 条
[1]   TRANSFORMATION AND VIRUS GROWTH BY MURINE SARCOMA VIRUSES IN HUMAN CELLS [J].
AARONSON, SA ;
TODARO, GJ .
NATURE, 1970, 225 (5231) :458-&
[2]  
ALMEIDA IC, 1991, J IMMUNOL, V146, P2394
[3]  
Ausubel FM., 2006, ENZYMATIC MANIPULATI
[4]   THE AIDS-ASSOCIATED RETROVIRUS IS NOT SENSITIVE TO LYSIS OR INACTIVATION BY HUMAN-SERUM [J].
BANAPOUR, B ;
SERNATINGER, J ;
LEVY, JA .
VIROLOGY, 1986, 152 (01) :268-271
[5]   HUMANS HAVE ANTIBODIES CAPABLE OF RECOGNIZING ONCOVIRAL GLYCOPROTEIN - DEMONSTRATION THAT THESE ANTIBODIES ARE FORMED IN RESPONSE TO CELLULAR MODIFICATION OF GLYCOPROTEINS RATHER THAN AS CONSEQUENCE OF EXPOSURE TO VIRUS [J].
BARBACID, M ;
BOLOGNESI, D ;
AARONSON, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (03) :1617-1621
[6]   MECHANISM OF ANTIBODY-INDEPENDENT ACTIVATION OF THE 1ST COMPONENT OF COMPLEMENT (CL) ON RETROVIRUS MEMBRANES [J].
BARTHOLOMEW, RM ;
ESSER, AF .
BIOCHEMISTRY, 1980, 19 (13) :2847-2853
[7]   LYSIS OF ONCORNAVIRUSES BY HUMAN-SERUM - ISOLATION OF VIRAL COMPLEMENT (C1) RECEPTOR AND IDENTIFICATION AS P15E [J].
BARTHOLOMEW, RM ;
ESSER, AF ;
EBERHARD, HJM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 147 (03) :844-853
[8]  
BOIRON RR, 1969, P AM ASSOC CANC RES, V10, P8
[9]   LYSIS OF RNA TUMOR-VIRUSES BY HUMAN-SERUM - DIRECT ANTIBODY-INDEPENDENT TRIGGERING OF CLASSICAL COMPLEMENT PATHWAY [J].
COOPER, NR ;
JENSEN, FC ;
WELSH, RM ;
OLDSTONE, MBA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 144 (04) :970-984
[10]   AMPHOTROPIC MURINE LEUKEMIA RETROVIRUS IS NOT AN ACUTE PATHOGEN FOR PRIMATES [J].
CORNETTA, K ;
MOEN, RC ;
CULVER, K ;
MORGAN, RA ;
MCLACHLIN, JR ;
STURM, S ;
SELEGUE, J ;
LONDON, W ;
BLAESE, RM ;
ANDERSON, WF .
HUMAN GENE THERAPY, 1990, 1 (01) :15-30